On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation.
alloantigen
basic (laboratory) research/science
cell death: exhaustion
immune regulation
immunosuppression/immune modulation
infection and infectious agents - viral: hepatitis C
infectious disease
liver allograft function/dysfunction
liver transplantation/hepatology
translational research/science
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
18
01
2020
revised:
03
06
2020
accepted:
03
06
2020
pubmed:
12
6
2020
medline:
22
6
2021
entrez:
12
6
2020
Statut:
ppublish
Résumé
Virus-induced heterologous immunity is considered a barrier to transplantation tolerance. Yet, hepatitis C (HCV)-infected liver transplant (LT) patients occasionally achieve operational tolerance. We investigated the mechanisms through which HCV infection modulates donor-specific T cell responses following LT and the influence of HCV eradication. We generated T cell lines from HCV-infected LT and non-LT patients before and after HCV eradication and quantified alloreactive responses using cell lines expressing single-HLA class-I antigens in the presence/absence of PD-1/CTLA-4 blockade. HCV-specific CD8
Identifiants
pubmed: 32524678
doi: 10.1111/ajt.16134
pii: S1600-6135(22)08334-4
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-257Subventions
Organisme : Cancer Research UK
ID : 26813
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15108
Pays : United Kingdom
Informations de copyright
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol. 2002;2(6):417-426.
Rowntree LC, Nguyen THO, Gras S, Kotsimbos TC, Mifsud NA. Deciphering the clinical relevance of allo-human leukocyte antigen cross-reactivity in mediating alloimmunity following transplantation. Curr Opin Organ Transplant. 2016;21(1):29-39.
Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol. 2007;7(12):942-953.
Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest. 2003;111(12):1887-1895.
Amir AL, D'Orsogna LJA, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood. 2010;115(15):3146-3157.
D’Orsogna LJ, Roelen DL, Doxiadis IIN, Claas FHJ. Alloreactivity from human viral specific memory T-cells. Transpl Immunol. 2010;23(4):149-155.
D’Orsogna L, van den Heuvel H, van Kooten C, Heidt S, Claas FHJ. Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms. Immunogenetics. 2017;69(8-9):631-641.
Gamadia LE, Remmerswaal EB, Surachno S, et al. Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules. Transplantation. 2004;77(12):1879-1885.
Macdonald WA, Chen Z, Gras S, et al. T cell allorecognition via molecular mimicry. Immunity. 2009;31(6):897-908.
Mifsud NA, Nguyen THO, Tait BD, Kotsimbos TC. Quantitative and functional diversity of cross-reactive EBV-specific CD8+ T cells in a longitudinal study cohort of lung transplant recipients. Transplantation. 2010;90(12):1439-1449.
Heutinck KM, Yong SL, Tonneijck L, et al. Virus-specific CD8 + T cells cross-reactive to donor-alloantigen are transiently present in the circulation of kidney transplant recipients infected with CMV and/or EBV. Am J Transplant. 2016;16(5):1480-1491.
Shi X-L, de Mare-Bredemeijer ELD, Tapirdamaz Ö, et al. CMV primary infection is associated with donor-specific T cell hyporesponsiveness and fewer late acute rejections after liver transplantation. Am J Transplant. 2015;15(9):2431-2442.
de Mare-Bredemeijer ELD, Shi X, Mancham S, et al. Cytomegalovirus-induced expression of CD244 after liver transplantation is associated with CD8+ T cell hyporesponsiveness to alloantigen. J Immunol. 2015;195(4):1838-1848.
Bohne F, Londono M-C, Benitez C, et al. HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. Sci Transl Med. 2014;6(242):242ra81.
Sanchez-Fueyo A, Markmann JF. Immune exhaustion and transplantation. Am J Transplant. 2016;16(7):1953-1957.
Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61(1):S14-S25.
Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119(7):1745-1754.
Rehermann B, Thimme R. Insights from antiviral therapy into immune responses to hepatitis B and C virus infection. Gastroenterology. 2019;156(2):369-383.
Cornberg M, Wedemeyer H. Hepatitis C virus infection from the perspective of heterologous immunity. Curr Opin Virol. 2016;16:41-48.
Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719-726.
Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204-1212.
Owusu Sekyere S, Schlevogt B, Mettke F, et al. HCC immune surveillance and antiviral therapy of hepatitis C virus infection. Liver Cancer. 2019;8(1):41-65.
Owusu Sekyere S, Suneetha PV, Hardtke S, et al. Type I interferon elevates co-regulatory receptor expression on CMV- and EBV-specific CD8 T cells in chronic hepatitis C. Front Immunol. 2015;6:270.
Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340(6129):207-211.
Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science. 2013;340(6129):202-207.
van den Heuvel H, van der Meer-Prins EMW, van Miert PPMC, Zhang X, Anholts JDH, Claas FHJ. Infection with a virus generates a polyclonal immune response with broad alloreactive potential. Hum Immunol. 2019;80(2):97-102.
Steger U, Denecke C, Sawitzki B, Karim M, Jones ND, Wood KJ. Exhaustive differentiation of alloreactive CD8+ T cells: critical for determination of graft acceptance or rejection. Transplantation. 2008;85(9):1339-1347.
Martin B, Hennecke N, Lohmann V, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol. 2014;61(3):538-543.
Wedemeyer H, He X-S, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8 + T cells in chronic hepatitis C virus infection. J Immunol. 2002;169(6):3447-3458.
Kared H, Saeed S, Klein MB, Shoukry NH. CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV Co-infected individuals. PLoS One. 2014;9(7):e101441.
Chan C, Schiano T, Agudelo E, et al. Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy. Am J Transplant. 2018;18(10):2506-2512.
Londoño M-C, Souza LN, Lozano J-J, et al. Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. J Hepatol. 2018;69(3):626-634.
Feng S, Bucuvalas JC, Demetris AJ, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants. Gastroenterology. 2018;155(6):1838-1851.e7.
Wieland D, Kemming J, Schuch A, et al. TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation. Nat Commun. 2017;8(1):15050.
McKinney EF, Lee JC, Jayne DRW, Lyons PA, Smith KGC. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612-616.
McKinney EF, Lyons PA, Carr EJ, et al. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med. 2010;16(5):586-591.
Wiedeman AE, Muir VS, Rosasco MG, et al. Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. J Clin Invest. 2019. https://doi.org/10.1172/JCI126595
Long SA, Thorpe J, DeBerg HA, et al. Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol. 2016;1(5):eaai7793.